AzTrials
AzTrials

Coronary Artery DiseaseNCT04888260

Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease

An observational study of Coronary Artery Disease and Hyperlipidemias, run by Kafkas University at 2 sites in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aims: Nondiabetic patients have been studied to determine whether modest elevations in plasma mannose levels may be associated with a greater incidence of coronary artery disease (CAD). Read more about this study

Who is it for?
Ages 18 to 100 yearsHealthy volunteers can take part
Conditions the study is for
Coronary Artery Disease, Hyperlipidemias
What is being tested?
Laboratory parameter levels in blood samples
How many people
240 participants
Where
2 sitesTurkey (Türkiye)
Study dates
10 Jan 2018to 15 May 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The patient and control groups will be initially informed about the study and obtained a written consent. Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment will be included in the patient group. The control group will be consisted of healthy people with normal coronary arteries angiographically. Patients with chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease will also be excluded. For this purpose, age and sex matched 120 patients and 120 healthy volunteers will be admitted to study.

Who may be able to join

  • To give written informed consent. To underwent angiography at the Pamukkale University Department of Cardiology. To have normal coronary angiography. Not to be on statin treatment.

Who cannot join

  • To be on statin treatment. To underwent angiography at the another department or university. Not to be newly diagnosed as coronary artery disease. To have a chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease.
  • For Control Group;
  • To be on statin treatment. To underwent angiography at the another department or university. To have a chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease.

Trial locations and contacts

2 sites in 1 country.

Turkey (Türkiye)2 sites
  • Aylin Koseler

    Denizli, Outside of the US, 20070

  • Ramazan Sabirli

    Kars, Outside of the US, 36000

Other trials in Turkey (Türkiye)

About this study

Official title: Associations Between Serum Lipids and Mannose Levels in Coronary Artery Disease Among Nondiabetic Patients

Aims: Nondiabetic patients have been studied to determine whether modest elevations in plasma mannose levels may be associated with a greater incidence of coronary artery disease (CAD).

Methods: The plasma mannose, lipids (triglyceride, LDL, HDL, LDL, VLDL) and LDH levels were successfully will be evaluated with respect to subsequent coronary artery disease using records 120 nondiabetic patients and 120 healthy volunteers. CAD was identified from myocardial infarction and new diagnoses of angina.

The associations between mannose levels and serum lipid parameters will be investigated.

Read the detailed description

Coronary artery disease (CAD), also known as coronary heart disease (CHD) or ischemic heart disease (IHD), entails a decrease of blood flow to the heart muscle as a result of plaque build-up in the arteries of the heart. CAD are among the world's leading causes of mortality and morbidity, following rapid change and advancement of cardiovascular diagnosis and treatment methods.

The broad range of lipid molecular species in human plasma and their possible role in human health and disease are topics of great interest. Plasma lipidome is now progressively recognized as a potentially important marker of chronic diseases, but the exact degree of its contribution to the interindividual phenotypic variation in family studies is uncertain .

Associative evidence gathered from plasma lipidomic studies promises vital contributions to biomarker research-an important cornerstone of ongoing efforts to prevent chronic disease. The plasma lipidomic profile of humans is associated with various conditions including obesity and disorders of glucose metabolism, hypertension , cardiovascular diseases.

Plasma lipids are solubilized and distributed by associating them with different protein groups. Most free fatty acids and associated structures with carboxyl functional groups interact with albumin, while more complex lipids are transported and distributed using plasma lipoproteins.

Glycerolipids account for a high proportion of total lipids in plasma and include triacylglycerols (TAGs), diacylglycerols (DAGs), and ether-linked glycerolipids. The total plasma concentration of TAGs, allocated between chylomicrons and very-low-density lipoprotein (VLDL), depends on food intake. It is well known that various acquired or secondary risk factors (including genetic determinants, uncontrolled diabetes mellitus, obesity, and sedentary lifestyle) can cause hypertriglyceridemia, a prevalent type of dyslipidemia that is often associated with premature coronary artery disease.

D-mannose, one of the stereoisomers forms, is a structural isomer of D-glucose and commonly found in biological systems, but L-mannose is generally not found in biological systems. Mannose is transported to mammalian cells by hexose transporters primarily by glucose transporters (GLUTs) present in the plasma membrane. Studies demonstrated that plasma mannose levels in human are associated with incident type 2 diabetes mellitus and cardiocascular diseases. On the other hand, molecular mechanism by which the pathway is induced is still unclear. A recent study showed that human plasma lipidome is pleiotropically associated with the cardiovascular risk factors and death.

In mammalian cells, mannose is joined in glycolysis and gluconeogenesis pathways catalyzed by mannose phosphate isomerase. Mannose is a constituent of normal blood plasma and its concentration is generally elevated in diabetes mellitus and chronic glomerulonephritis . However, studies showed that fructose and mannose levels are significantly reduced in obese individuals . Currently, we have reported that elevated baseline mannose in plasma triggered to GLUT4 and Heksokinase-1 (HK1) associated with a progressive risk of CAD with time.

A cytoplasmic enzyme of lactate dehydrogenase (LDH) found in all body cells which transfers a hydride from one molecule to another. LDH catalyzes the reversible conversion of pyruvate to lactate as a unit of Cori cycle. A cardiac marker of LDH is expressed extensively in body cells and a marker of heart failure .

The aims of the study were to determine whether modest elevations in plasma mannose concentrations, and serum lipids [triglyceride, low density lipoprotein (LDL), high density lipoprotein (HDL) and very-low density lipoprotein (VLDL)] may be associated with a greater incidence of CAD among nondiabetic patients. Because hyperglycemia and/or hydrophilicity is associated with additional risk factors for CAD including hypertension, obesity, aging. Additionally, identifying the molecular and biochemical parameters in plasma associated with risk factors for CAD may have strategic importance in the treatment of these diseases.

The patient and control groups will be initially informed about the study and obtained a written consent. Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment will be included in the patient group. The control group will be consisted of healthy people with normal coronary arteries angiographically. Patients with chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease will be also excluded. For this purpose, age and sex matched 120 patients and 120 healthy volunteers will be admitted to study.

Blood samples will be collected as described earlier into EDTA and citrate vacutainers.Total cholesterol, high-density lipoprotein and triglycerides will be measured by a commercially available enzymatic colorimetric assay (Roche, Basel,Switzerland). Glucose, creatinine and the other blood profiles will be determined by standard methods.The samples will be centrifuged at 400xg for 10 min to separate the serum.Biochemical parameters will be measured by using an Abbott ARCHITECH c800(Abbott Laboratories, USA) auto analyser and commercial kits. Serum mannose levels will be determined by enzymatic methods using in the ELISA.

Kolmogrov-Smirnov test will be used to determine whether the group was parametrically distributed. Categorical variables were given as numbers and percentages. If the parameters are parametrically distributed, continuous variables will be expressed as mean ± standard deviation; if the parameters are non-parametrically distributed, continuous variables will be expressed as median (IQR). When parametric test assumptions will be provided, the significance test of difference between two means and one-way analysis of variance will be used to compare independent group differences. When parametric test assumptions were not provided, Mann-Whitney U test will be used to compare independent group differences. The relationships between continuous variables will be analyzed using Spearman correlation analysis, chi-square test will be used for analyzing categorical variables. Furthermore, Receiver Operating Characteristic (ROC) curve analysis was used for the discriminant performance serum mannose levels under investigation. In addition, the relationships between continuous variables will be examined by Spearman correlation analysis. P <0.05 will be considered statistically significant in all examinations.

Being tested
Laboratory parameter levels in blood samples
Medical subject headings
Coronary Artery Disease, Hyperlipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Laboratory parameter levels in blood samplesOther

    Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.

Study groups in NCT04888260
Study groupRoleWhat they receive
Coronary Artery Disease GroupPatients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
Receives: Other: Laboratory parameter levels in blood samples
Control GroupThe control group consisted of healthy people with normal coronary arteries angiographically
Receives: Other: Laboratory parameter levels in blood samples

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlations between mannose levels and serum lipid parameters

    This outcome aims to investigate the correlations between mannose levels and serum lipid parameters in patients who have body mass index under than 25 (kg/m^2) and over than 25 kg/m^2.

    Measured: 16 Months

Secondary outcomes (2)
  1. Correlations between mannose levels and infection parameters (CRP and others).

    This outcome aims to investigate the correlations between mannose levels and serum infection parameters(CRP and others) in patients who have body mass index under than 25 (kg/m^2) and over than 25 kg/m^2.

    Measured: 6 months

  2. The effect of comorbidites on correlation between the serum mannose levels and serum lipid parameters and serum infecition parameters

    This outcome aims to investigate the effect of comorbidites on correlation between the serum mannose levels and serum lipid parameters and serum infecition parameters in patients who have body mass index under than 25 (kg/m^2) and over than 25 kg/m^2 and in patient who have hypertension disease.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2021
  2. Study start10 Jan 2018
  3. Primary completion10 May 2020
  4. Study completion15 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
240 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04888260
Sponsor's protocol ID
Clinical-4
Status last verified
May 2021
First submitted
7 May 2021
Last updated
17 May 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Plan is undecided.

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease and Hyperlipidemias, run by Kafkas University at 2 sites in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlations between mannose levels and serum lipid parameters (time frame: 16 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in